Abstract
Background In the global outbreak of coronavirus disease 2019 (COVID-19), new digital solutions have been developed for infection control. In particular, contact tracing mobile applications provide a means for governments to manage both health and economic concerns. However, public reception of these applications is paramount to success, and global take-up rates have been low.
Objective In this study, we sought to identify sociodemographic factors predicting voluntary downloads of a contact tracing mobile application.
Methods A sample of 505 adults from the general community completed an online survey. As the primary outcome measure, participants indicated whether they had downloaded a contact tracing application introduced at the national level (“TraceTogether”). As predictor variables, we assessed: (1) participant demographics; (2) behavioral changes on account of the pandemic; and (3) pandemic severity (the number of cases and lockdown status).
Results Within our dataset, the strongest predictor of digital contact tracing take-up was the extent to which individuals had already adjusted their lifestyles because of the pandemic (Z = 13.97, p < .001). Network analyses revealed that take-up was most related to: using hand sanitizers, avoiding public transport, and preferring outdoor over indoor venues during the pandemic. However, demographic and situational characteristics did not significantly predict application downloads.
Conclusions Efforts to introduce contact tracing applications could capitalize on pandemic-related behavioral adjustments that individuals have made. Given that critical mass is needed for contact tracing to be effective, we urge further research to understand how citizens respond to contact tracing applications.
Trial Registration ClinicalTrials.gov NCT04468581
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04468581
Funding Statement
This research was funded by a grant awarded to JCJL from the JY Pillay Global Asia Programme (grant number: IG20-SG002).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Yale-NUS College Ethics Review Committee (#2020-CERC-001)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are available on request from the corresponding author (JCJL). The data are not publicly available due to IRB restrictions.